Meridian Bioscience Expands Canadian Molecular Diagnostics Portfolio with Health Canada License for Alethia® CMV Assay
Meridian Bioscience, Inc., a global provider of diagnostic testing solutions and life science raw materials, has announced that Health Canada has granted a license for its Alethia® Cytomegalovirus (CMV) assay, marking an important milestone in the company’s continued expansion of molecular diagnostic solutions in the Canadian healthcare market. The regulatory authorization broadens Meridian’s Alethia molecular testing menu while providing healthcare laboratories and clinicians across Canada with access to a rapid diagnostic tool designed to support the early detection of congenital cytomegalovirus (CMV) infections.
The newly licensed assay strengthens Meridian’s growing portfolio of molecular diagnostics by adding CMV testing to the Alethia platform’s existing menu, which already includes assays for Clostridioides difficile (C. difficile), Group A Streptococcus, Group B Streptococcus, malaria, Mycoplasma pneumoniae, and Bordetella pertussis. With the addition of CMV, Canadian healthcare providers now have another diagnostic option capable of delivering timely and accurate molecular results that can support evidence-based clinical decision-making.
Expanding Access to Molecular Diagnostics in Canada
Molecular diagnostics continue to transform modern healthcare by enabling clinicians to identify infectious diseases quickly and accurately. Rapid testing allows physicians to make informed treatment decisions sooner, improving patient management while helping healthcare organizations optimize laboratory workflows.
Health Canada’s approval of the Alethia CMV assay represents another step forward in expanding access to advanced molecular diagnostic technologies throughout Canada. By extending the capabilities of the Alethia platform, Meridian Bioscience reinforces its commitment to supporting healthcare professionals with diagnostic tools that combine speed, simplicity, and analytical performance.
The expanded testing menu allows laboratories already using the Alethia system to perform additional molecular assays without requiring significant changes to existing workflows or investments in larger laboratory infrastructure.
Supporting Earlier Detection of Congenital CMV
One of the primary clinical applications of the Alethia CMV assay is the detection of congenital cytomegalovirus infections in newborns.
Cytomegalovirus is one of the most common viral infections worldwide and is particularly significant during pregnancy because the virus can be transmitted from an infected mother to her developing baby. Congenital CMV remains the most common congenital infection globally and is an important cause of long-term health complications in infants.
Although many maternal CMV infections occur without noticeable symptoms, transmission during pregnancy can result in congenital infection, which may affect newborn hearing, vision, neurological development, and overall health.
Early identification of congenital CMV is therefore considered essential for ensuring that infants receive appropriate medical evaluation, monitoring, and clinical management as early as possible.
The availability of a rapid molecular assay designed specifically for congenital CMV testing provides healthcare professionals with valuable diagnostic information during the critical period immediately following birth.
Importance of Early Diagnosis
Early diagnosis plays a crucial role in the management of congenital CMV.
Many newborns infected with CMV appear healthy at birth, making diagnosis difficult without laboratory testing. However, some infants may later develop hearing loss, developmental delays, vision impairment, or neurological complications that could benefit from earlier recognition and ongoing medical monitoring.
Prompt molecular testing allows healthcare providers to identify infected infants before they leave the hospital, enabling physicians to establish follow-up care plans, recommend additional evaluations, and discuss potential treatment options with families when appropriate.
By supporting earlier detection, the Alethia CMV assay contributes to more informed clinical decision-making during one of the most important stages of neonatal healthcare.
Growing Awareness of Congenital CMV
Despite its prevalence, congenital CMV remains relatively unknown among many expectant parents.
Public health organizations have increasingly emphasized the need for greater awareness of congenital CMV because early diagnosis and education may help improve health outcomes for affected infants.
Many pregnant women remain unfamiliar with CMV transmission, associated risks, and preventive measures, even though maternal infection is relatively common.
Healthcare providers therefore continue to advocate for improved education alongside expanded diagnostic capabilities that facilitate timely identification of congenital infections.
The availability of accessible molecular testing solutions supports these broader public health efforts by making early diagnosis more practical for hospitals and clinical laboratories.
Rapid Results to Support Clinical Decisions
The Alethia molecular platform has been designed to deliver clinically meaningful results in less than one hour.
Fast turnaround times are increasingly important in healthcare settings where physicians must make treatment decisions quickly and efficiently.
Traditional laboratory testing methods often require longer processing times or specialized laboratory infrastructure that may delay diagnosis.
In contrast, rapid molecular testing enables clinicians to receive reliable diagnostic information during the patient’s initial clinical evaluation or shortly thereafter.
For newborn CMV screening, this rapid availability of results can significantly improve communication between healthcare providers and families before hospital discharge.
A Compact Platform for Modern Laboratories
Healthcare laboratories today face increasing pressure to improve efficiency while managing rising testing volumes, staffing shortages, and budget constraints.
Meridian designed the Alethia platform to address many of these operational challenges through a compact instrument footprint and streamlined testing workflow.
Rather than requiring highly complex laboratory processes, the system enables laboratories to perform molecular testing using simplified procedures that reduce hands-on time while maintaining analytical accuracy.
Its relatively small physical footprint also makes the platform suitable for a variety of laboratory environments, including hospitals, regional laboratories, and facilities with limited laboratory space.
This flexibility allows more healthcare organizations to incorporate molecular diagnostics into routine clinical practice.
Utilizing LAMP Technology
A distinguishing feature of the Alethia platform is its use of Loop-Mediated Isothermal Amplification (LAMP) technology.
Unlike traditional polymerase chain reaction (PCR) methods that require repeated temperature cycling, LAMP amplifies nucleic acids at a constant temperature.
This approach simplifies instrument design while maintaining high analytical sensitivity and specificity for detecting infectious pathogens.
Because LAMP technology does not require complex thermal cycling equipment, it may offer a more cost-effective solution for healthcare laboratories seeking reliable molecular diagnostic capabilities.
The technology has become increasingly valuable for infectious disease testing due to its speed, efficiency, and ease of implementation across diverse laboratory settings.
Simplifying Specimen Collection
Another advantage of the Alethia CMV assay is its use of saliva specimens for congenital CMV testing.
Saliva collection provides a convenient, non-invasive sampling method that is particularly well suited for newborn screening.
Compared with more invasive specimen collection techniques, saliva sampling can be performed quickly and comfortably while minimizing stress for infants and healthcare providers.
Simple specimen collection may also improve workflow efficiency within maternity units and neonatal care settings where timely testing is essential.
By combining straightforward sample collection with rapid molecular analysis, the assay helps streamline the overall diagnostic process.
Supporting Healthcare Providers and Families
The introduction of the Alethia CMV assay provides benefits beyond laboratory efficiency.
For physicians, access to accurate molecular diagnostics supports confident clinical decision-making during neonatal care.
For families, earlier diagnosis offers greater clarity regarding a newborn’s health status before discharge from the hospital.
Receiving timely diagnostic information enables parents and caregivers to better understand potential health considerations while allowing healthcare providers to recommend appropriate follow-up evaluations when necessary.
This collaborative approach supports improved communication between clinicians and families during an important stage of newborn care.
Strengthening Meridian’s Molecular Diagnostics Portfolio
The addition of CMV further expands Meridian Bioscience’s comprehensive portfolio of infectious disease diagnostics.
The Alethia platform already supports testing for several clinically significant pathogens, including infections responsible for respiratory disease, gastrointestinal illness, and streptococcal infections.
By continually expanding its molecular assay menu, Meridian enables healthcare laboratories to consolidate multiple diagnostic capabilities onto a single platform.
This broader menu improves laboratory flexibility while increasing the value of existing Alethia installations.
Healthcare organizations can therefore perform a wider range of molecular tests without investing in multiple diagnostic platforms.
Responding to Evolving Healthcare Needs
Healthcare systems continue placing greater emphasis on rapid diagnosis, evidence-based medicine, and improved patient outcomes.
As infectious disease surveillance becomes increasingly important, laboratories require molecular diagnostic solutions that balance speed, accuracy, affordability, and operational simplicity.
Meridian’s expansion of the Alethia menu reflects these evolving healthcare priorities by providing laboratories with practical molecular testing capabilities that integrate efficiently into routine clinical workflows.
The Health Canada license also demonstrates the company’s continued investment in regulatory approvals that expand patient access to advanced diagnostic technologies internationally.
The licensing of the Alethia® CMV assay by Health Canada represents a significant advancement for Meridian Bioscience’s presence in the Canadian molecular diagnostics market. By expanding the Alethia platform with a rapid assay for congenital cytomegalovirus detection, the company strengthens its ability to support healthcare providers, clinical laboratories, and hospitals with reliable diagnostic solutions.
As awareness of congenital CMV continues to grow, demand for accurate and timely testing is expected to increase. The Alethia CMV assay positions Meridian to address this need by delivering highly sensitive molecular detection, simplified saliva specimen collection, and rapid turnaround times that support evidence-based clinical care.
Beyond expanding its diagnostic menu, Meridian’s latest regulatory milestone reflects its broader mission of improving patient care through innovative molecular diagnostics. With an emphasis on workflow efficiency, laboratory accessibility, and clinically actionable results, the Alethia platform continues to evolve as a versatile solution for infectious disease testing. The addition of congenital CMV testing further enhances its role in helping healthcare professionals diagnose infections earlier, guide treatment decisions more effectively, and improve health outcomes for newborns and their families across Canada.
Source link: https://www.businesswire.com/
